Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
•
Anal Cancer
What would you include in your radiation field for a cT2N1 perianal squamous cell carcinoma in the setting of VIN3, CIN3 and AIN3?
Related Questions
Given the results of PLATO anal cancer study, is 4140 cGy the new standard for early stage anal cancer?
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
Given that ESOPEC did not mandate PET staging, are the conclusions of the study still applicable for patients who are staged with PET?
What treatment sequence do you follow for patients with rectal cancer who are candidates for both PROSPECT and TNT/Watch and wait?
How would you treat a patient with synchronous node positive prostate cancer (T3bN1M0) and oligometastatic rectosigmoid cancer (T4aN1M1) with a solitary liver metastasis?
Would you change treatment approach for rectal cancer with an associated intussusception?
What would be your radiotherapy plan for an overall stage IIA, low lying, MMRd rectal adenocarcinoma to try to avoid APR?
Would you dose escalate neoadjuvant radiotherapy for T3 and/or N+ rectal cancer in patients who are unwilling or unable to get chemotherapy?
What are your top takeaways from ASCO GI 2025?
How would you approach unexpected chemo breaks during planned neoadjuvant chemoradiation for esophageal adenocarcinoma?
